SITE014-0032

SITE014 (NLD) › SITE014-0032

SITE014-0032

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2025-10-05

enrolled

AEs

4

Serious

1

Dropout signal

–

Adverse events

4

Grade 4 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-11-22 (study day 227); relationship: not assessed; serious criteria: life-threatening

severe serious assessed

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-11-08 (study day 213); relationship: not assessed

moderate assessed

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-10-30 (study day 204); relationship: NOT RELATED

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-02 (study day 84); relationship: RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.